Roche Addresses WHO’s Global Health Emergency Declaration Amid Ongoing Mpox Outbreak
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced its commitment to supporting the global response to the mpox health emergency by providing diagnostic tests specifically developed for mpox, formerly known as…
EU Approves Second Indication for TEPKINLY in Treating Relapsed/Refractory Follicular Lymphoma
AbbVie (NYSE: ABBV) has announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for adult patients with relapsed or refractory (R/R) follicular…
Tirzepatide Cuts Type 2 Diabetes Risk by 94% in Adults with Pre-Diabetes and Obesity or Overweight
Eli Lilly and Company (NYSE: LLY) announced today positive top-line results from the SURMOUNT-1 three-year study, which evaluated the long-term efficacy and safety of tirzepatide (Zepbound® and Mounjaro®) for weight…
Medea Inc. Teams Up with CalOptima Health to Distribute 100,000 Naloxone Units to Southern California Harm Reduction Groups
Medea Inc., a leading medical products and pharmaceutical distribution company, is at the forefront of a major initiative to tackle the opioid crisis. The company is partnering with CalOptima Health…
UptimeHealth and Darby Dental Supply Collaborate to Introduce Darby Dispatch: A New Solution for Improving Efficiency and Compliance in Dental Practices Across the Country
UptimeHealth, a leader in healthcare technology solutions, is excited to announce a strategic partnership with Darby Dental Supply, a top dental distributor in the U.S. This collaboration introduces Darby Dispatch,…
Daiwa Health Development, Inc. to Host Webinar with Dr. Fred Pescatore on Clinical Applications of RBAC
Daiwa Health Development, Inc. Announces Webinar with Dr. Fred Pescatore on Clinical Applications of RBAC Daiwa Health Development, Inc. is thrilled to host an upcoming webinar featuring Dr. Fred Pescatore,…
AmorSui Secures $3.5M Seed Funding to Transform Sustainable Medical Supplies
AmorSui, a cutting-edge personal protective equipment (PPE) brand committed to safeguarding both people and the planet, has announced a successful $3.5 million seed funding round. This investment will propel AmorSui’s…
AN2 Therapeutics Implements Limited-Term Shareholder Rights Plan
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics from its boron chemistry platform, has announced the adoption of a limited-duration stockholder rights plan. This…
IMFINZI® (durvalumab) Gains US Approval for Pre- and Post-Surgery Treatment of Resectable Non-Small Cell Lung Cancer
AstraZeneca’s IMFINZI® (durvalumab) Approved in the US for Comprehensive Treatment of Resectable Non-Small Cell Lung Cancer AstraZeneca has announced that IMFINZI® (durvalumab), in combination with chemotherapy, has received approval from…
Agendia Receives CE-IVDR Certification for MammaPrint® and BluePrint® Breast Cancer Assays
Agendia is pleased to announce that it has achieved certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three of its products: the MammaPrint® FFPE…
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
Incyte (Nasdaq: INCY) today reported positive results from the pivotal Phase 3 inMIND study, which evaluated the efficacy and safety of tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19-targeted monoclonal antibody,…
Pfizer and BioNTech Announce Update on mRNA Combination Vaccine Program for Influenza and COVID-19 in Adults Aged 18-64
BioNTech SE (Nasdaq: BNTX) today revealed top-line results from their Phase 3 clinical trial evaluating a combined mRNA vaccine candidate against influenza and COVID-19 in healthy adults aged 18-64. This…